Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

User: Guest

Title:: Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1
Document type:: Zeitschriftenaufsatz
Author(s):: Huhn, Gregory D.; Wilkin, Aimee; Mussini, Cristina; Spinner, Christoph D.; Jezorwski, John; El Ghazi, Mohsine; Van Landuyt, Erika; Lathouwers, Erkki; Brown, Kimberley; Baugh, Bryan
Journal title:: HIV Research & Clinical Practice
Year:: 2020
Journal volume:: 21
Journal issue:: 6
Pages contribution:: 151-167
Fulltext / DOI:: doi:10.1080/25787489.2020.1844520
Publisher:: Informa UK Limited
E-ISSN:: 2578-74892578-7470
Date of publication:: 01.11.2020
BibTeX

Occurrences: